Drug development

What Are the Chances of FDA Approval After Phase 2?

A typical drug that completes Phase 2 has historically had well under even odds of approval. For an individual drug, the real question is which factors move its odds above or below that average.

Key points

  • Historically, a drug entering Phase 2 has had roughly a 15% chance of approval. A drug that has already advanced into Phase 3 has had roughly a 52% chance.
  • Disease area is one of the largest factors: odds from Phase 2 range from about 10% to about 34% across major areas.
  • Biomarker-selected patient populations, rare diseases, and human genetic support for the drug's target are all associated with higher success rates.
  • The quality of the Phase 2 result matters as much as its direction: a randomized, controlled result on a meaningful endpoint is far more informative than an uncontrolled signal.
  • FDA expedited designations signal regulatory interest but do not guarantee approval.

"What are the chances this drug gets approved?" is the question investors, patients, and researchers ask most often about a drug that has just finished Phase 2. Historical data gives a starting point. A useful answer for a specific drug comes from understanding what moves the odds up or down from there.

Two different questions

"After Phase 2" can mean two different things, and the odds are very different:

Situation Historical chance of approval
A drug entering Phase 2 About 15%
A drug that succeeded in Phase 2 and has advanced to Phase 3 About 52%

Source: BIO, Informa Pharma Intelligence, QLS Advisors (2021), likelihood-of-approval table (Figure 5b): 15.1% from Phase 2 and 52.4% from Phase 3.

The difference is the Phase 2 result itself. A positive Phase 2 readout removes the single largest source of risk, but a drug that reaches Phase 3 still fails roughly half the time. For how these averages are built, see What Percentage of Phase 2 Drugs Get Approved?

Factors that move the odds

1. Disease area

Disease area is one of the largest factors in the historical data. In the BIO analysis, the calculated chance of approval from Phase 2 ranged from about 34% in hematology to about 10% in oncology and cardiovascular disease. The disease area sets the baseline before anything about the drug itself is considered.

2. Patient selection

Programs that used biomarkers to select patients, the core idea of precision medicine, roughly doubled their odds from Phase 2 (about 30% versus about 15% in the BIO data). If a drug's Phase 2 result came from a biomarker-defined group and its Phase 3 trial enrolls that same group, the result is more likely to hold up.

3. Rare disease

The BIO report found that therapies for rare diseases had an overall likelihood of approval from Phase 1 of 17.0%, more than double the all-disease average of 7.9%. Therapies for chronic, highly prevalent diseases had just 5.9%. Rare-disease programs often target a well-understood genetic cause and can use regulatory flexibility designed for small populations.

4. Genetic support for the target

Drug programs whose target is supported by human genetic evidence have been about 2.6 times more likely to succeed in clinical development than programs without it, according to a 2024 analysis in Nature. Genetic evidence is a sign that the target genuinely matters in human disease, the assumption Phase 2 is designed to test.

5. Quality of the Phase 2 evidence

Not all positive Phase 2 results are equal. Signals that a result is more likely to replicate:

  • Randomized and controlled, with a placebo or active comparator.
  • Prespecified primary endpoint, met as planned, rather than a positive finding in a subgroup or secondary measure found after the fact.
  • Clinically meaningful endpoint, or a surrogate endpoint the FDA accepts.
  • Dose response, where higher doses produced larger effects, which suggests the drug is causing the effect.
  • Consistency across subgroups and across more than one trial.

Warning signs include results from an uncontrolled single-arm study, a "trend" that missed statistical significance, or an effect seen only after excluding some patients.

6. The Phase 3 plan

Look at whether Phase 3 will test the same thing that succeeded. A common source of failure is a Phase 3 trial that changes the endpoint, broadens the population, or compares against a stronger treatment than Phase 2 did. See Why Do Phase 3 Clinical Trials Fail?

7. Regulatory designations

Designations such as Breakthrough Therapy or Fast Track show that the FDA considers the drug promising for a serious condition. They bring more frequent FDA interaction and can speed review. They do not lower the standard of evidence needed for full approval, and they do not guarantee success.

8. Sponsor resources and strategy

Some programs stop for business reasons, not science. In a study of 640 novel therapeutics that entered pivotal trials between 1998 and 2008, 22% of failures were attributed to commercial reasons. A sponsor with limited cash, or a program that has fallen down a larger company's priority list, faces risk unrelated to the data.

Putting it together

A sound estimate for an individual drug starts with the historical rate for comparable programs, such as the same phase and disease area, and then adjusts for the evidence specific to that drug. Simply quoting an industry-wide average treats every Phase 2 program as identical. Simply trusting a company's description of its own results ignores how often promising Phase 2 data fails to replicate.

Spectral Genomics publishes historical benchmarks, labeled as such, rather than drug-specific predictions. Our approval odds methodology explains where the figures come from and how to read them.

Sources

  1. Biotechnology Innovation Organization, Informa Pharma Intelligence, QLS Advisors. Clinical Development Success Rates and Contributing Factors 2011–2020 (2021).Industry report
  2. Minikel EV, Painter JL, Dong CC, Nelson MR. Refining the impact of genetic evidence on clinical success. Nature. 2024;629:624–629.Peer-reviewed
  3. Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Internal Medicine. 2016;176(12):1826–1833.Peer-reviewed
  4. U.S. Food and Drug Administration. Guidance: Expedited Programs for Serious Conditions: Drugs and Biologics (2014).Regulator
  5. Wong CH, Siah KW, Lo AW. Estimation of clinical trial success rates and related parameters. Biostatistics. 2019;20(2):273–286.Peer-reviewed

This article is for education. It is not medical advice and not investment advice. Figures are drawn from the sources above and describe historical averages, not the prospects of any particular drug. See our editorial standards and disclaimer.